What is it about?
Randomized large trial with very long follow-up comparing overall and cardiovascular mortality and morbidity of Mircea with EPO alfa;EPO beta and Darbopoetin
Featured Image
Why is it important?
It is the randomized trial with the longest follow-up on the field
Perspectives
The results of this trial should have important clinical impact in selecting the ESAS, considering that a recent observational study on Registry data suggested different conclusions
Francesco Locatelli
Read the Original
This page is a summary of: Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD, Clinical Journal of the American Society of Nephrology, August 2019, American Society of Nephrology,
DOI: 10.2215/cjn.01380219.
You can read the full text:
Contributors
The following have contributed to this page
